Prev: Prostate cancer patients undergoing hormone therapy may experience cognitive effects
Next: Recent review articles about brain cancer (InTextoResearch)
From: scimedweb on 2 Aug 2008 13:56
Recent review articles about breast cancer:


HER2-positive breast cancer: current treatment strategies.
Perez EA, Baweja M.
Cancer Invest. 2008 Jul;26(6):545-52.

Current issues in ER and HER2 testing by IHC in breast cancer.
Gown AM.
Mod Pathol. 2008 May;21 Suppl 2:S8-S15.

Is 'basal-like' carcinoma of the breast a distinct clinicopathological
entity? A critical review with cautionary notes.
Moinfar F.
Pathobiology. 2008;75(2):119-31.

Impact of basal-like breast carcinoma determination for a more
specific therapy.
Rakha EA, Reis-Filho JS, Ellis IO.
Pathobiology. 2008;75(2):95-103.

Cancer stem cells in breast: current opinion and future challenges.
Charafe-Jauffret E, Monville F, Ginestier C, Dontu G, Birnbaum D,
Wicha MS.
Pathobiology. 2008;75(2):75-84.

Comparative genomic hybridisation arrays: high-throughput tools to
determine targeted therapy in breast cancer.
Tan DS, Reis-Filho JS.
Pathobiology. 2008;75(2):63-74.

"Stemness" genomics law governs clinical behavior of human cancer:
implications for decision making in disease management.
Glinsky GV.
J Clin Oncol. 2008 Jun 10;26(17):2846-53.

Survival of the fittest: cancer stem cells in therapeutic resistance
and angiogenesis.
Eyler CE, Rich JN.
J Clin Oncol. 2008 Jun 10;26(17):2839-45.

Implications of the cancer stem-cell hypothesis for breast cancer
prevention and therapy.
Kakarala M, Wicha MS.
J Clin Oncol. 2008 Jun 10;26(17):2813-20.

Poor usage of HUGO standard gene nomenclature in cancer marker
studies.
Lacroix M.
Int J Biol Markers. 2008 April - June;23(2):123-126.

Neurokinin receptors as potential targets in breast cancer treatment.
Reddy BY, Trzaska KA, Murthy RG, Navarro P, Rameshwar P.
Curr Drug Discov Technol. 2008 Mar;5(1):15-9.

Inhibition of receptor tyrosine kinases in combination with
chemotherapy for the treatment of breast cancer.
Moulder SL, Craft BS, Hortobagyi GN.
Anticancer Agents Med Chem. 2008 Jun;8(5):481-7.

Meta-analysis confirms BCL2 is an independent prognostic marker in
breast cancer.
Callagy GM, Webber MJ, Pharoah PD, Caldas C.
BMC Cancer. 2008 May 29;8:153.

The taxane limbo: how low can we go?
Hudis C, Dang C.
J Natl Cancer Inst. 2008 Jun 4;100(11):761-3.

Novel cytotoxic agents: epothilones.
Goodin S.
Am J Health Syst Pharm. 2008 May 15;65(10 Suppl 3):S10-5.

Estrogen-induced breast oncogenesis: modulation by an Aurora kinase
inhibitor.
Li SA, Lam LK, Ahmed N, Hontz AE, Li JJ.
Adv Exp Med Biol. 2008;617:213-20.

The origin of estrogen receptor alpha-positive and alpha-negative
breast cancer.
Clarke RB, Sims AH, Howell A.
Adv Exp Med Biol. 2008;617:79-86.

What can we learn about breast cancer from stem cells?
Clarke MF.
Adv Exp Med Biol. 2008;617:17-22.

Relevance of the concept of oncogene addiction to hormonal
carcinogenesis and molecular targeting in cancer prevention and
therapy.
Weinstein B.
Adv Exp Med Biol. 2008;617:3-13.

A role for Numb in p53 stabilization.
Carter S, Vousden KH.
Genome Biol. 2008;9(5):221.

Ixabepilone: a new microtubule-targeting agent for breast cancer.
Higa GM, Abraham J.
Expert Rev Anticancer Ther. 2008 May;8(5):671-81.

Adverse bone effects during pharmacological breast cancer therapy.
Bjarnason NH, Hitz M, Jorgensen NR, Vestergaard P.
Acta Oncol. 2008;47(4):747-54.

Raloxifene in breast cancer prevention.
Gennari L, Merlotti D, Paola VD, Nuti R.
Expert Opin Drug Saf. 2008 May;7(3):259-70.


(contact at InTextoResearch: Marc Lacroix, Baelen, Wallonia, Belgium -
scimedweb(a)mail.com)
 | 
Pages: 1
Prev: Prostate cancer patients undergoing hormone therapy may experience cognitive effects
Next: Recent review articles about brain cancer (InTextoResearch)